Vertex Pharmaceuticals Inc
$515.91
$1.27 (+0.25%)
$511.90Day Range$517.95
Key Statistics
Market Cap
$130.44B
Shares Outstanding
253.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 31, 1991
Round Lot
40
Locale
US
Trading Data
Day Open
$513.80
Day High
$517.95
Day Low
$511.90
Volume
295.4K
VWAP
$514.97
Prev Close
$514.63
Transactions
--
Acc. Volume
--
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
PHARMACEUTICAL PREPARATIONSSIC 28346,400 employees50 NORTHERN AVENUE, BOSTON, MA, 02210(617) 341-6393IPO Jul 31, 1991US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000875320
- Composite FIGI
- BBG000C1S2X2
- Share Class FIGI
- BBG001S68LJ8
- Ticker Root
- VRTX
- SIC Code
- 2834
About Vertex Pharmaceuticals Inc (VRTX) Stock
Vertex Pharmaceuticals Inc (VRTX) closed the 2026-09-16 session at $515.90, up 0.25% versus the previous close (+1.27). The stock opened at $513.80 and traded between $511.90 and $517.95 during that session. Session trading volume was 295K shares. The volume-weighted average price (VWAP) is $514.97.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Vertex Pharmaceuticals Inc has a market capitalization of $130.44 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. VRTX is listed on the XNAS exchange. The company employs approximately 6,400 people. Vertex Pharmaceuticals Inc is headquartered in BOSTON, MA. The recorded listing date is 1991-07-31.
On this page you can find market VRTX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.